Gouda MA, Subbiah V. Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers. Ther Adv Med Oncol. 2023;15:2621751.

Article  Google Scholar 

Gandhi MM, Ricciuti B, Harada G, Repetto M, Gildenberg MS, Singh A, Li YY, Gagne A, Wang X, Aizer A, Fitzgerald K, Nishino M, Alessi J, Pecci F, Di Federico A, Fisch A, Drilon A, Nardi V, Sholl L, Awad MM, Rotow J. Amplification of wild-type RET represents a novel molecular subtype of several cancer types with clinical response to selpercatinib. Jco Precis Oncol. 2023;7:e2300295.

Article  PubMed  PubMed Central  Google Scholar 

Drilon A, Hu ZI, Lai G, Tan D. Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. Nat Rev Clin Oncol. 2018;15(3):151–67.

Article  CAS  PubMed  Google Scholar 

Attwa MW, Alrabiah H, Mostafa G, Bakheit AH, Kadi AA. Assessment of in silico and in vitro selpercatinib metabolic stability in human liver microsomes using a validated LC-MS/MS method. Molecules. 2023;28(6):2618.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oliveira L, Mulligan LM. Selpercatinib: first approved selective RET inhibitor. Cell. 2023;186(8):1517.

Article  CAS  PubMed  Google Scholar 

Kadoya M, Suganuma N, Matsubara Y, Takase H, Kumagai E, Toda S, Yamazaki H, Masudo K, Fujii S, Saito A. Selpercatinib for treating recurrent mixed medullary and follicular cell-derived thyroid carcinoma: a case report. Surg Case Rep. 2024;10(1):92.

Article  PubMed  PubMed Central  Google Scholar 

Deschler-Baier B, Konda B, Massarelli E, Hu MI, Wirth LJ, Xu X, et al. Clinical activity of selpercatinib in RET-mutant pheochromocytoma. J Clin Endocr Metab. 2024:dgae283.

Drilon A, Subbiah V, Gautschi O, Tomasini P, de Braud F, Solomon BJ, Shao-Weng TD, Alonso G, Wolf J, Park K, Goto K, Soldatenkova V, Szymczak S, Barker SS, Puri T, Bence LA, Loong H, Besse B. Selpercatinib in patients With RET fusion-positive non-small-cell lung cancer: updated safety and efficacy from the registrational LIBRETTO-001 phase I/II trial. J Clin Oncol. 2023;41(2):385–94.

Article  CAS  PubMed  Google Scholar 

Huang Y, Dai S, Yin W, Luo F, Li Y. Sustained clinical response to 4th-line therapy with selpercatinib in RET fusion-positive combined small cell lung cancer. Oncotargets Ther. 2023;16:1015–20.

Article  Google Scholar 

Park HY, Park JH, Shin MG, Han SJ, Ji YS, Oh HJ, Kim YC, Lee T, Choi YD, Oh IJ. Case report: a case of ultra-late recurrence of KIF13A-RET fusion non-small cell lung cancer response to selpercatinib. Front Oncol. 2023;13:1178762.

Article  PubMed  PubMed Central  Google Scholar 

Schrenk KG, Weschenfelder W, Spiegel C, Agaimy A, Stohr R, Hartmann A, Gassler N, Drescher R, Freesmeyer M, Malouhi A, Burckenmeyer F, Aschenbach R, Teichgraber U, Kogler C, Vogt M, Hofmann GO, Hochhaus A. Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma. J Cancer Res Clin. 2023;149(9):5493–6.

Article  CAS  Google Scholar 

Jozaghi Y, Zafereo M, Williams MD, Gule-Monroe MK, Wang J, Grubbs EG, Vaporciyan A, Hu MI, Busaidy N, Dadu R, Waguespack SG, Subbiah V, Cabanillas M. Neoadjuvant selpercatinib for advanced medullary thyroid cancer. Head Neck-J Sci Spec. 2021;43(1):E7–12.

Article  Google Scholar 

Matrone A, Prete A, Sartini MS, Elisei R. Significant response of medullary thyroid cancer choroidal metastases to highly selective RET inhibitor selpercatinib: a case report. Ann Oncol. 2021;32(11):1447–9.

Article  CAS  PubMed  Google Scholar 

Le D, Konda B. Selpercatinib for adult patients with locally advanced or metastatic RET-altered solid tumors. Expert Rev Anticanc. 2023;23(11):1117–22.

Article  CAS  Google Scholar 

Jazdarehee A, Abdel-Rahman O, Jacquier JE. Remission of ectopic cushing syndrome secondary to medullary thyroid cancer with vandetanib and selpercatinib. JCEM Case Rep. 2024;2(2):d174.

Article  Google Scholar 

Cognigni V, Giudice GC, Bozzetti F, Milanese G, Moschini I, Casali M, Mazzaschi G, Tiseo M. Successful treatment with selpercatinib after pralsetinib-related pneumonitis and intracranial failure in a patient with RET-rearranged nonsmall cell lung cancer. Anti-Cancer Drug. 2024;35(6):559–62.

Article  CAS  Google Scholar 

De Carlo E, Bertoli E, Schiappacassi M, Stanzione B, Del CA, Doliana R, Spina M, Bearz A. Case report: first evidence of impressive efficacy of modulated dose selpercatinib in a young Caucasian with ANK3-RET fusion-positive NSCLC. Front Oncol. 2024;14:1307458.

Article  PubMed  PubMed Central  Google Scholar 

Duke ES, Bradford D, Marcovitz M, Amatya AK, Mishra-Kalyani PS, Nguyen E, Price L, Fourie ZJ, Li Y, Bi Y, Kraft J, Dorff SE, Scepura B, Stephenson M, Ojofeitimi I, Nair A, Han Y, Tezak Z, Lemery SJ, Pazdur R, Larkins E, Singh H. FDA approval summary: selpercatinib for the treatment of advanced RET Fusion-positive solid tumors. Clin Cancer Res. 2023;29(18):3573–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nie T, Syed YY. Selpercatinib: a review in advanced RET fusion-positive NSCLC. Target Oncol. 2023;18(1):169–76.

Article  PubMed  Google Scholar 

Nguyen VQ, Geirnaert M. An overview of the role of selpercatinib and pralsetinib in RET-fusion-positive non-small cell lung cancer (NSCLC). J Oncol Pharm Pract. 2023;29(2):450–6.

Article  CAS  PubMed  Google Scholar 

Scattolin D, Scagliori E, Scapinello A, Fantin A, Guarneri V, Pasello G. Small bowel edema and lymphocytic duodenitis as severe reversible gastrointestinal toxicity of selpercatinib in RET fusion-positive non-small cell lung cancer: a case report. Front Oncol. 2023;13:1201599.

Article  PubMed  PubMed Central  Google Scholar 

Cheng Y, Huang D, Zhou J, Zhou C, Sun Y, Wu L, Guo Y, Jingxin S, Zhang W, Lu S. Intracranial activity of selpercatinib in chinese patients with advanced ret fusion-positive non-small-cell lung cancer in the phase II LIBRETTO-321 trial. Jco Precis Oncol. 2023;7:e2200708.

Article  PubMed  PubMed Central  Google Scholar 

Qi Y, Li J, Lin S, Wu S, Chai K, Jiang X, Qian J, Jiang C. A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib. Sci Rep-Uk. 2024;14(1):11388.

Article  CAS  Google Scholar 

Zhou C, Peng S, Lin A, Jiang A, Peng Y, Gu T, Liu Z, Cheng Q, Zhang J, Luo P. Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. Eclinicalmedicine. 2023;59:101967.

Article  PubMed  PubMed Central  Google Scholar 

Ziegengeist JL, Elmes JB, Strassels SA, Patel JN, Moore DC. Alpelisib-induced diabetic ketoacidosis: a pharmacovigilance analysis of the FDA adverse event reporting system and review of the literature. Clin Breast Cancer. 2024;24(4):e204–9.

Chen Z, Li M, Li S, Li Y, Wu J, Qiu K, Yu X, Huang L, Chen G. A pharmacovigilance analysis of FDA adverse event reporting system events for romosozumab. Expert Opin Drug Saf. 2023;22(4):339–42.

Article  CAS  PubMed  Google Scholar 

Li Z, Guo C, Liu X, Qiu Z, Zhang R. Post-marketing safety evaluation of lurbinectedin: a pharmacovigilance analysis based on the FAERS database. Front Pharmacol. 2024;15:1368763.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tang L, Ding C, Li H, Yin G, Zhang H, Liu WS, et al. A pharmacovigilance study of adverse event profiles and hemorrhagic safety of bevacizumab based on the FAERS database. Expert Opin Drug Saf. 2023;23(2):213–20.

Article  PubMed  Google Scholar 

Wu XP, Lu XK, Wang ZT, Huang L, Cai RW, Yu HM, et al. Post-marketing safety concerns with upadacitinib: a disproportionality analysis of the FDA adverse event reporting system. Expert Opin Drug Saf. 2023;22(10):975–84.

Article  CAS  PubMed  Google Scholar 

Jiang C, Qian J, Jiang X, Zhang S, Zheng J, Wang H. Is pitolisant safe for clinical use? A retrospective pharmacovigilance study focus on the post-marketing safety. Pharmacol Res Perspe. 2024;12(1):e1161.

Article  CAS  Google Scholar 

Shu Y, Ding Y, Liu Y, Wu P, He X, Zhang Q. Post-marketing safety concerns with secukinumab: a disproportionality analysis of the FDA adverse event reporting system. Front Pharmacol. 2022;13:862508.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shu Y, He X, Wu P, Liu Y, Ding Y, Zhang Q. Gastrointestinal adverse events associated with semaglutide: a pharmacovigilance study based on FDA adverse event reporting system. Front Public Health. 2022;10:996179.

Article  PubMed  PubMed Central